Catherine M. Burzik Elected as BD Director

                  Catherine M. Burzik Elected as BD Director

PR Newswire

FRANKLIN LAKES, N.J., Jan. 29, 2013

FRANKLIN LAKES, N.J., Jan. 29, 2013 /PRNewswire/ --BD (Becton, Dickinson and
Company) (NYSE:BDX), a leading global medical technology company, announced
that Catherine M. Burzik has been elected to its Board of Directors.

Ms. Burzik, 62, is a seasoned healthcare executive with leadership experience
in medical device, diagnostic, diagnostic imaging and life sciences
businesses. Most recently, from 2006 until the sale of the company in 2012,
she served as President, Chief Executive Officer and Director of Kinetic
Concepts, Inc., a medical device company specializing in woundcare and
regenerative medicine. Her prior positions include service as President of
Applied Biosystems, a leading DNA sequencing company, as well as senior
positions at Eastman Kodak and Johnson & Johnson.

"I am pleased and honored to welcome Catherine Burzik to the BD Board," said
Vincent A. Forlenza, BD Chairman, Chief Executive Officer and President.
"Cathy has a strong and diversified background in several key sectors of the
healthcare industry, as well as extensive knowledge of the global healthcare
arena. I know that she will make important strategic contributions to the
Board as we evaluate the many opportunities BD has to continue innovating to
improve healthcare around the world."

Ms. Burzik currently serves as Chair of the Board of Directors of VitaPath
Genetics, Inc. and is a member of the San Antonio Branch of the Dallas Federal
Reserve Board. She also serves as Chair, Canisius College Board of Trustees
and is a member of the Board of Directors of ViroXis Corporation and the Board
of Trustees of Keck Graduate School of Applied Life Sciences.

Ms. Burzik received a bachelor's degree in Mathematics from Canisius College
and a masters' degree in Mathematics from the University of Buffalo.

About BD
BD is a leading global medical technology company that develops, manufactures
and sells medical devices, instrument systems and reagents. The Company is
dedicated to improving people's health throughout the world. BD is focused on
improving drug delivery, enhancing the quality and speed of diagnosing
infectious diseases and cancers, and advancing research, discovery and
production of new drugs and vaccines. BD's capabilities are instrumental in
combating many of the world's most pressing diseases. Founded in 1897 and
headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000
associates in more than 50 countries throughout the world. The Company serves
healthcare institutions, life science researchers, clinical laboratories, the
pharmaceutical industry and the general public. For more information, please
visit www.bd.com.

Contacts:
Colleen T. White, Corporate Communications – 201-847-5369;
colleen_white@bd.com
Monique N. Dolecki, Investor Relations – 201-847-5378;
monique_dolecki@bd.com

SOURCE BD (Becton, Dickinson and Company)

Website: http://www.bd.com
 
Press spacebar to pause and continue. Press esc to stop.